A subanalysis of the ENGAGE AF-TIMI 48 (Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation—Thrombolysis in Myocardial Infarction 48) trial also looked at the combination of a NOAC plus APT [14]. The gene discussed is F10; the disease is atrial fibrillation.